Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.

MLA

Dal Negro, R. W., et al. “Efficacy of Erdosteine 900 versus 600 Mg/Day in Reducing Oxidative Stress in Patients with COPD Exacerbations: Results of a Double Blind, Placebo-Controlled Trial.” Pulmonary Pharmacology & Therapeutics, vol. 33, Aug. 2015, pp. 47–51. EBSCOhost, https://doi.org/10.1016/j.pupt.2015.06.004.

APA

Dal Negro, R. W., Visconti, M., & Turco, P. (2015). Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial. Pulmonary Pharmacology & Therapeutics, 33, 47–51. https://doi.org/10.1016/j.pupt.2015.06.004

Chicago

Dal Negro, R W, M Visconti, and P Turco. 2015. “Efficacy of Erdosteine 900 versus 600 Mg/Day in Reducing Oxidative Stress in Patients with COPD Exacerbations: Results of a Double Blind, Placebo-Controlled Trial.” Pulmonary Pharmacology & Therapeutics 33 (August): 47–51. doi:10.1016/j.pupt.2015.06.004.